Hangzhou Alltest Biotech Co. Ltd. A (688606) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hangzhou Alltest Biotech Co. Ltd. A (688606) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥55.21 Million ≈ $8.08 Million USD) by net assets (CN¥3.90 Billion ≈ $570.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Hangzhou Alltest Biotech Co. Ltd. A to measure how much of total assets are equity-financed.
Hangzhou Alltest Biotech Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Hangzhou Alltest Biotech Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Hangzhou Alltest Biotech Co. Ltd. A to evaluate the quality of earnings relative to operating cash generation.
Hangzhou Alltest Biotech Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hangzhou Alltest Biotech Co. Ltd. A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SEALSQ Corp
NASDAQ:LAES
|
-0.117x |
|
Cub Elecparts Inc
TW:2231
|
0.005x |
|
Community Healthcare Trust Inc
NYSE:CHCT
|
0.033x |
|
Shanghai Golden Bridge
SHG:603918
|
0.043x |
|
Caregen Co.Ltd
KQ:214370
|
0.019x |
|
Leon Technology Co Ltd
SHE:300603
|
0.047x |
|
Topkey Corp
TW:4536
|
0.026x |
|
AGI Greenpac Limited
NSE:AGI
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Hangzhou Alltest Biotech Co. Ltd. A (2016–2025)
The table below shows the annual cash flow conversion efficiency of Hangzhou Alltest Biotech Co. Ltd. A from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 688606 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.95 Billion ≈ $577.47 Million |
CN¥206.59 Million ≈ $30.23 Million |
0.052x | -38.30% |
| 2024-12-31 | CN¥3.88 Billion ≈ $568.27 Million |
CN¥329.52 Million ≈ $48.22 Million |
0.085x | +1212.89% |
| 2023-12-31 | CN¥3.83 Billion ≈ $560.68 Million |
CN¥24.76 Million ≈ $3.62 Million |
0.006x | -98.02% |
| 2022-12-31 | CN¥4.17 Billion ≈ $610.34 Million |
CN¥1.36 Billion ≈ $199.11 Million |
0.326x | +15.60% |
| 2021-12-31 | CN¥3.27 Billion ≈ $479.04 Million |
CN¥923.87 Million ≈ $135.19 Million |
0.282x | -55.92% |
| 2020-12-31 | CN¥972.66 Million ≈ $142.33 Million |
CN¥622.72 Million ≈ $91.12 Million |
0.640x | +105.08% |
| 2019-12-31 | CN¥293.20 Million ≈ $42.90 Million |
CN¥91.53 Million ≈ $13.39 Million |
0.312x | +261.00% |
| 2018-12-31 | CN¥215.10 Million ≈ $31.48 Million |
CN¥18.60 Million ≈ $2.72 Million |
0.086x | -40.04% |
| 2017-12-31 | CN¥138.61 Million ≈ $20.28 Million |
CN¥19.99 Million ≈ $2.93 Million |
0.144x | -41.34% |
| 2016-12-31 | CN¥27.32 Million ≈ $4.00 Million |
CN¥6.72 Million ≈ $982.82K |
0.246x | -- |
About Hangzhou Alltest Biotech Co. Ltd. A
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; flu… Read more